Search
Search
The groundbreaking AvaGen™, The Genetic Eye Test, leverages powerful genetic information to provide eyecare professionals with an early and accurate understanding of keratoconus genetic risk, and the presence of TGFBI gene-related corneal dystrophies. AvaGen delivers a valuable tool for early and accurate decision-making that protects and improves vision for patients and their families.
.00_00_31_24.Still001_1633117824.png?auto=compress,format&w=504)
Sponsored Content
.00_19_42_06.Still001_1633118071.png?auto=compress,format&w=504)
Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Sponsored Content
Identifying Keratoconus Risk with Genetic Testing
AvaGen™, The Genetic Eye Test in Modern Practice
AvaGen Genetic Test Brochure for ECPs
AvaGen Patient Brochure
How CXL and Genetic Testing Fit Into the Keratoconus Game Plan
Genetic Testing Builds Confidence
Common Questions Patients Ask Genetic Counselors and How to Talk to Them About Testing
How are innovations in genetic testing affecting eyecare?
[Genetics and Eyecare Today] How Genetic Data Can Help Guide Decisions
[Genetics and Eyecare Today] The Role of Genetic Testing and Early Keratoconus Diagnosis
About Avellino
Avellino Lab USA, Inc. is a global leader in gene therapy and molecular diagnostics at the forefront of precision medicine for eye care and beyond. With a long-term mission to develop personalized approaches to improve health and disease management through genomics, the company is developing a transformative genetic diagnostics product pipeline, as well as gene therapeutics leveraging CRISPR gene editing, to better manage, and potentially cure, inherited diseases. Avellino is the first privately held, independent company to get an FDA Emergency Use Authorization (EUA).
Visit us online: avellino.com/en/ | avellino.com/en/products/avagen-test/
Follow Avellino
© 2021 Avellino.com All rights reserved.
